Grifols has filed for US approval of a new drug for rare bleeding disorder acquired fibrinogen deficiency (AFD), which promises to provide a more reliable and easier treatment for patients.

Grifols is gearing up to file for approval of a drug for rare bleeding disorder acquired fibrinogen deficiency (AFD) that could provide a more reliable and easier treatment for patients.

Another important aspect of recent studies is the investigation of genetic mutations affecting fibrinogen ... the mechanisms of autoimmune-acquired Factor XIII deficiency (AiF13D).

The new application covers both supplementation in patients with acquired fibrinogen deficiency and treatment and prophylaxis of acute bleeding episodes in all patients with congenital fibrinogen ...

for the treatment of acquired fibrinogen deficiency (AFD). The company now plans to complete European Medicines Agency (EMA) and US Food and Drug Administration (FDA) regulatory submissions ...

The new application covers both supplementation in patients with acquired fibrinogen deficiency and treatment and prophylaxis of acute bleeding episodes in all patients with congenital fibrinogen ...

for supplementation in bleeding patients with acquired fibrinogen deficiency, said drugmaker Octapharma. Across three states from August 2022-July 2023, the veterinary anesthetic medetomidine was ...